Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.64 |
| ▸ | CDK7 | P50613 | 2/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CDK9 | P50750 | 1/20 | 0.64 |
| ▸ | CCNH | P51946 | 1/20 | 0.64 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | NEK2 | P51955 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | LYN | P07948 | 2/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27491045 | 0.84 | CDK2 (0.73) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL8855125 | 0.84 | CDK2 (0.72) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL28251677 | 0.83 | CDK2 (0.70) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL8855120 | 0.80 | CDK2 (0.67) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL16171 | 0.78 | CDK2 (0.64) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL31346834 | 0.77 | CDK2 (0.62) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL8542833 | 0.77 | CDK2 (0.62) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL31229672 | 0.77 | CDK2 (0.62) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL13256589 | 0.75 | CDK2 (0.60) | CDK2CDK1CDK7CCNT1CCNB1 | |
| SCHEMBL3026520 | 0.75 | CDK2 (0.60) | CDK2CDK1CDK7NEK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100519507-C | Gallic acid derivative and its preparation method | COUNCIL SCIENT IND RES (IN) | 2009-07-29 | — | — | CN | claimed |
| CN-1213047-C | Puring derivatives inhibitors of tyrosine kinase SYK | NOVARTIS AG (CH) | 2005-08-03 | — | — | CN | claimed |
| CN-1365360-A | purine derivative inhibitors of tyrosine protein kinase SYK | NOVARTIS AG (CH) | 2002-08-21 | — | — | CN | claimed |
| CN-117770053-A | Fertilizing and planting method for mangoes in karst area | 中国地质调查局昆明自然资源综合调查中心 | 2024-03-29 | — | — | CN | disclosed |
| CN-107556389-B | Plant transactivation interaction motifs and uses thereof | 陶氏益农公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-107567503-A | Prognostic biomarkers for TTK inhibitor chemotherapy | 荷兰转化研究中心有限责任公司 | 2018-01-09 | — | — | CN | disclosed |
| CN-107001376-A | The compound for the treatment of cancer | 拜耳制药股份公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-105408332-B | Substituted triazolopyridines | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-103408546-A | 2-phenylaminopurine PLK1 (Polo-like kinase 1) inhibitors and applications thereof | UNIV CHINA PHARMA | 2013-11-27 | — | — | CN | disclosed |
| CN-103408546-A | 2-phenylaminopurine PLK1 (Polo-like kinase 1) inhibitors and applications thereof | UNIV CHINA PHARMA | 2013-11-27 | — | — | CN | disclosed |
| CN-100519507-C | Gallic acid derivative and its preparation method | COUNCIL SCIENT IND RES (IN) | 2009-07-29 | — | — | CN | disclosed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| WO-2002102769-A2 | METHODS FOR SYNTHESIZING SUBSTITUTED PYRIMIDINES | UNIVERSITY OF MASSACHUSETTS (US) | 2002-12-27 | — | — | WO | disclosed |
| CN-1365360-A | purine derivative inhibitors of tyrosine protein kinase SYK | NOVARTIS AG (CH) | 2002-08-21 | — | — | CN | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| CN-1062902-C | Fatty acyl reductases | CALGENE INC (US) | 2001-03-07 | — | — | CN | disclosed |
| CN-1064312-A | FATTY ACYL REDUCTASES | CALGENE INC (US) | 1992-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | TYMP, NUDT1, TYMS | CDK2 151/4885CDK1 491/4885CDK7 164/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CDK2 13/4885CDK1 4/4885CDK7 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.